1. Oğuz E, Bektaş M. Characteristics of patients with Behçet disease from the Van province, eastern Turkey: Definition of disease clusters in a tertiary referral center. J Clin Rheumatol. 2023. doi:10.1097/RHU.0000000000001996

2. Oğuz E, et al. Characteristics and course of patients with AA amyloidosis: Single centre experience with 174 patients from Turkey. Rheumatology (Oxford). 2024;63(2):319-328. doi:10.1093/rheumatology/kead465

3. Oğuz E, et al. Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: A controlled study. Clin Exp Rheumatol. 2024;42(2):358-366. doi:10.55563/clinexprheumatol/9u122p

4. Bektaş M, Özer MD, Oğuz E. The safety and efficacy of TNF inhibitors in patients with Behçet’s disease: Retrospective study from eastern Turkey. Clin Immunol. 2024;264:110239. doi:10.1016/j.clim.2024.110239

5. Oğuz E, Koca N, Bektaş M. Presence of myositis-specific autoantibodies may predict favorable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study. Mod Rheumatol. 2025 (ahead of print). doi:10.1093/mr/roaf097

6. Oğuz E, et al. Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis. J Clin Pharm Ther. 2022;47(2):257-259. doi:10.1111/jcpt.13504

7. Oğuz E, et al. Activation-induced cytidine deaminase expression in patients with chronic myeloid leukemia Experimed. 2022;12(3):155-159

8. Oğuz E, et al. Üçüncü basamak bir hastanede takip edilen COVID-19 olgularında immünosüpresif tedavi uygulanan hastaların değerlendirilmesi. Klimik Dergisi. 2022

ULUSLARARASI KONGRE SUNUMLARI (ACR)

9. Oğuz E, et al. Classification of idiopathic inflammatory myopathies: Assessment according to 2017 ACR/EULAR criteria. Arthritis Rheumatol. 2018;70(Suppl 9)

10. Oğuz E, et al. Favourable response to rituximab in IgG4-related disease: Long-term follow-up. Arthritis Rheumatol. 2018;70(Suppl 9)

11. Bektaş M, et al., Oğuz E. PET imaging in idiopathic inflammatory myositis: A case-control study. Arthritis Rheumatol. 2021;73(Suppl 9)

12. Toz B, et al., Oğuz E. IL-1 inhibitors in FMF-associated amyloidosis: Retrospective analysis. Arthritis Rheumatol. 2016;68(Suppl 10

Spec. Emi̇n OĞUZ, M.D.